Annual Report FY26 and 20th AGM Notice submitted to exchanges
ERIS · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.2 pts less than Nifty Smallcap 250 and 1.5 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Eris Lifesciences filed FY26 Annual Report and 20th AGM notice (Sept 25, 2026). Consolidated revenue Rs 3,129 cr (up 8 percent), EBITDA Rs 1,120 cr (up 10 percent), margin 35.8 percent vs 35.2 percent. PAT from operations Rs 498 cr (up 34 percent); reported PAT Rs 648 cr aided by Rs 150 cr one-off deferred tax gain. Domestic Branded Formulations grew 11 percent. Insulin and GLP-1 franchise up 32 percent. Front-loaded about Rs 400 cr in capex.
Strong FY26 with double-digit profit growth from operations, margin expansion, and aggressive capex for biologics and GLP-1. One-off tax gain flatters reported PAT.